Welcome to our dedicated page for Cv Sciences SEC filings (Ticker: CVSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CV Sciences, Inc. (OTCQB:CVSI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports and other documents that explain its financial condition, capital structure, and material agreements. CV Sciences presents itself as a consumer wellness company focused on hemp extracts, nutraceuticals, and plant-based foods, and its filings offer detail on how this strategy is reflected in its operations and financing.
Recent Form 8-K filings describe material events such as note purchase agreements and secured promissory notes with institutional investors. These reports outline original issuance discounts, net proceeds, maturity dates, repayment schedules, and security interests in the assets of CV Sciences and its subsidiaries. They also summarize customary events of default, potential increases to outstanding balances upon default, and the circumstances under which amounts can be declared immediately due and payable.
Other 8-K filings incorporate by reference the company’s earnings press releases, which include GAAP financial statements and non-GAAP measures like Adjusted EBITDA. In these disclosures, CV Sciences explains why management uses non-GAAP metrics, how they reconcile to GAAP results, and how they are intended to highlight trends in the business.
Through Stock Titan, users can review these filings alongside AI-powered summaries that clarify key terms in note purchase agreements, security agreements, and intellectual property security agreements. The platform also helps surface important items in quarterly and annual reports, such as product sales, gross margin, operating income or loss, and cash flow trends, without requiring readers to parse every line of the underlying documents.
Investors interested in CVSI can use this page to monitor new 8-Ks and other SEC submissions as they are posted to EDGAR, while AI-generated insights provide plain-language explanations of complex financing structures and reporting conventions.
CV Sciences, Inc. reported Q3 results marked by softer sales and tight liquidity while taking steps to refinance debt and reduce obligations. Product sales, net were
Cash was
Management disclosed substantial doubt about continuing as a going concern and noted new federal legislation effective
CV Sciences, Inc. furnished an 8‑K announcing it issued a press release covering financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference into Item 2.02 via Item 7.01.
The release includes non‑GAAP financial measures with GAAP reconciliations and related explanations. The information is furnished, not filed, and includes forward‑looking statements that are subject to risks and uncertainties.
FAQ
What is the current stock price of Cv Sciences (CVSI)?
What is the market cap of Cv Sciences (CVSI)?
